profit from every $100 of sales.
$0$100
Lifecore Biomedical
$6.37+0.16% today
-7.0% in 1 year
1-year low $3.661-year high $8.82
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Lifecore Biomedical sold, what it kept, and what it did with the cash.
Sales went from $111 million in 2022 to $129 million in 2025, with -$38.7 million of profit last year.
SalesProfit
Lifecore Biomedical vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Lifecore Biomedical | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.6× · Expensive |
AI analysis
An AI analyst reads Lifecore Biomedical's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 111 | 103 | 128 | 129 | |
| 39 | 28 | 42 | 40 | |
| -3 | -20 | -7 | -12 | |
| 13 | -33 | 36 | -8 | |
| -117 | -100 | 12 | -39 | |
| -3.30 | -3.41 | 0.32 | -1.27 | |
| 35.1% | 27.1% | 32.6% | 31.3% | |
| -3.1% | -19.1% | -5.6% | -9.3% | |
| -104.9% | -96.4% | 9.4% | -30.0% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | – | 254 | 254 | 239 |
| Cash | – | 19 | 8 | 8 |
| Total debt | – | 113 | 129 | 131 |
| Total liabilities | – | 258 | 243 | 238 |
| – | -4 | 11 | 1 | |
| 30 | 30 | 37 | 35 | |
| – | -33.8% | 15.6% | -9.9% | |
| – | 2,353.7% | 106.2% | -2,898.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -23 | -17 | 0 | -0 | |
| 30 | 21 | 18 | 13 | |
| -53 | -39 | -18 | -14 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 3 | 4 | 6 | 10 |
Valuation
- –
- –
- –
- 7.9×
- 1.9×
- –
- –
- -5.6%
- -16.0%
- 0.0%
Profitability
- 31.3%
- -9.3%
- -30.0%
- 2.0%
- -0.0%
- -31.1%
- -146.7%
- -15.1%
- -0.0%
- 5.6%
Growth
- +5.0%
- –
- +24.9%
- –
- +4.4%
Financial health
- –
- 7.23
- 66.6%
- -0.0×
- 3.79
- 2.41
- 0.60
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 37%of 948
Bottom 16%of 871
Bottom 27%of 868
Bottom 18%of 985
What analysts expect
- Average price target
- $6.00
- Range
- $6.00 – $6.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | -0.43 | -0.29 | −48.3% |
| Mar 16, 2026 | -0.16 | -0.29 | +44.8% |
| Nov 6, 2025 | -0.29 | -0.30 | +3.3% |
| Aug 7, 2025 | -0.10 | -0.09 | −11.1% |
| Apr 3, 2025 | -0.19 | -0.14 | −35.7% |
| Jan 2, 2025 | -0.25 | -0.27 | +7.4% |
| Aug 26, 2024 | -0.15 | -0.12 | −25.0% |
| Aug 9, 2024 | -0.41 | -0.12 | −241.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
13No pass
Benjamin Graham
20No pass
Philip Fisher
17No pass
Peter Lynch
9No pass
Joel Greenblatt
0No pass
Charlie Munger
15No pass
Terry Smith
20No pass
Questions about Lifecore Biomedical
Is Lifecore Biomedical a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Lifecore Biomedical AI analysis
What does Lifecore Biomedical do?
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. It is in Drug Manufacturers - Specialty & Generic.
Does Lifecore Biomedical pay a dividend?
No. Lifecore Biomedical does not pay a dividend at the moment.
Is Lifecore Biomedical stock halal?
No. Lifecore Biomedical does not pass our halal screen: its debt is 54% of its market value, at or above the 33% limit. How we check
How has Lifecore Biomedical stock done over the past year?
Down 7.0% over the past twelve months, to $6.37. It traded between $3.66 and $8.82 and is 27.8% below its high.
Who are Lifecore Biomedical's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Lifecore Biomedical's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.